| DIRECT COMPETITOR COMPARISON | |
| AMRN | ELN | MRK | TGEN | Industry | | Market Cap: | 34.62M | 3.10B | 77.79B | 4.79M | 160.43M | | Employees: | 28 | 1,687 | 55,200 | 58 | 103 | | Qtrly Rev Growth (yoy): | N/A | 6.30% | 1.80% | 113.00% | 20.50% | | Revenue (ttm): | N/A | 1.08B | 23.37B | 11.33M | 46.74M | | Gross Margin (ttm): | N/A | 50.57% | 76.36% | 25.68% | 56.06% | | EBITDA (ttm): | -27.56M | 26.80M | 7.81B | -1.99M | -7.12M | | Oper Margins (ttm): | N/A | -4.49% | 26.63% | -24.59% | 2.25% | | Net Income (ttm): | -20.02M | 51.00M | 8.05B | -4.65M | N/A | | EPS (ttm): | -0.907 | 0.106 | 3.808 | -0.228 | -0.17 | | P/E (ttm): | N/A | 59.43 | 9.68 | N/A | 15.74 | | PEG (5 yr expected): | N/A | N/A | 2.18 | N/A | 1.04 | | P/S (ttm): | N/A | 2.87 | 3.27 | 0.42 | 4.17 |
|
| ELN = Elan Corp. plc | | MRK = Merck & Co. Inc. | | TGEN = Targeted Genetics Corp. | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 1.30% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.84 | 1.92% | 13.84B | 16.01 | | Genzyme Corp. | GENZ | 51.11 | 0.81% | 13.56B | 29.14 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.40 | 0.63% | 41.76B | 17.94 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.76 | 1.97% | 9.05B | 1035.92 | | Teva Pharmaceutical Industries Limited | TEVA | 53.38 | 1.12% | 47.03B | 48.84 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.55 | 1.24% | 3.99B | 19.36 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.89 | 0.51% | 2.95B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.23 | 2.01% | 5.57B | 111.84 | | Pfizer Inc. | PFE | 18.85 | 3.74% | 152.11B | 15.66 | | Johnson & Johnson | JNJ | 63.51 | 1.07% | 175.23B | 13.87 | | GlaxoSmithKline plc | GSK | 42.41 | 2.27% | 107.51B | 13.51 | | Sanofi-Aventis | SNY | 39.32 | 3.58% | 102.67B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 56.16 | 1.01% | 127.55B | 16.81 | | RHHBY.PK | 41.40 | 1.17% | N/A | N/A | | AstraZeneca plc | AZN | 45.74 | 2.03% | 66.32B | 9.18 | | Abbott Laboratories | ABT | 54.48 | -0.02% | 84.27B | 14.76 | | Bristol-Myers Squibb Co. | BMY | 24.65 | -2.61% | 48.83B | 12.75 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | MRK | | IBD's Top 10 - Tuesday
Tue 7:24pm -
Investor's Business Daily | | • | MRK | | FDA approves OTC version of heartburn drug Zegerid
Tue 7:12pm -
AP | | • | MRK | | JPMorgan Chase, Merck: Money Flow Leaders (JPM, MRK)
Tue 6:03pm -
at The Wall Street Journal Online | | • | MRK | | Santarus shares rise on FDA drug approval
Tue 5:38pm -
at MarketWatch | | • | MRK | | InPlay: Merck: FDA approves ZEGERID OTC for over-the-counter treatment of frequent heartburn
Tue 5:35pm -
Briefing.com | | • | ELN | | Report from Europe: Dubai Out -- December In
Tue 11:00am -
at Seeking Alpha | | • | ELN | | Research Firm Lays Out Surprise Bio Events for 2010: BioBuzz
Mon, Nov 30 -
at TheStreet.com | | • | ELN | | 4 Platform Drugmakers to Invest In
Tue, Nov 24 -
at Motley Fool | | • | TGEN | | TARGETED GENETICS CORP /WA/ Financials
Sat, Nov 21 -
EDGAR Online Financials | | • | ELN | | UPDATE - HealthCor slams Biogen CEO for outsize pay package
Fri, Nov 20 -
at Reuters | | • | TGEN | | Targeted Genetics reports $671K net income in Q3
Mon, Nov 16 -
at bizjournals.com | | • | TGEN | | TARGETED GENETICS CORP /WA/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
Mon, Nov 16 -
EDGAR Online | | • | TGEN | | Targeted Genetics Corporation Reports Third Quarter 2009 Financial Results
Mon, Nov 16 -
Business Wire | | • | ELN | | Thursday Options Recap
Thu, Nov 12 -
at Seeking Alpha | | • | ELN | | When Rival Drug Makers Compare Notes On Safety Problems
Wed, Nov 11 -
at The Wall Street Journal Online | | • | ELN | | Cramer's Lightning Round - The Only Water Stock Worth Buying (11/10/09)
Wed, Nov 11 -
at Seeking Alpha | | • | ELN | | Lightning Round: Priceline.com, Citigroup, Transocean and More
Tue, Nov 10 -
at CNBC | | • | ELN | | Elan to Present at Lazard Capital Markets 6th Annual Healthcare Conference
Tue, Nov 10 -
Business Wire | | • | TGEN | | Targeted Genetics sheds some office space
Thu, Nov 5 -
at bizjournals.com | | | All Headlines for these symbols... |
|
|
|
1.23% Nasdaq 
0.07 (5.19%) 
Competitors
